In Vivo Pharmacodynamic Evaluation of Clarithromycin in Comparison to Erythromycin

Abstract The efficacy of various dosing regimens of clarithromycin and erythromycin against recently isolated Streptococcus pneumoniae strains was determined In Vivo using two animal infection models (mouse peritonitis and thigh infection). For the thigh infection model, mice received a total dose of 4 mg/Kg of either clarithromycin or erythromycin, as a single total dose or divided into 2, 4 or 8 doses/24h. After 24h of therapy S. pneumoniae organisms were killed at 2.06 to 4.03 log10 CFU/thigh by clarithromycin and the one- or two-dose regimens were significantly more effective than the four- or eight-dose regimens. Organism killing following 24h of therapy with erythromycin ranged from 1.13 to 2.31 log10 CFU/thigh, with the one- or two-dose regimens significantly less effective than the four- or eight-dose regimens. In the mouse survival study, the same dose of either clarithromycin or erythromycin was given as a single total dose or divided into two or four doses with dosing intervals of 4 and 2-times the t1/2 respectively. The results obtained in this model show that there is a significant difference in survival when clarithromycin is administered less frequently (4% deaths for the one-dose regimen in comparison to 40% deaths with the four-dose regimen, P<0.01, Chisquare test). With erythromycin there was a trend for increased survival with the multiple-dose regimen, with significantly higher survival when concentrations exceeding the MIC were maintained for a longer time period. These results indicate that the time during which serum concentrations exceeding the MIC value of the pathogen is an important parameter for efficacy for erythromycin. On the contrary, results with both animal models demonstrate that bacterial killing and survival are significantly higher among clarithromycin-treated mice when the antibiotic is administered less frequently and the highest Cmax/MIC ratio is achieved.

[1]  D. Xuan,et al.  Pharmacodynamic Assessment of Clarithromycin in a Murine Model of Pneumococcal Pneumonia , 2002, Antimicrobial Agents and Chemotherapy.

[2]  T. Mazzei,et al.  Pharmacokinetics of Dirithromycin in Patients with Mild or Moderate Cirrhosis , 1999, Antimicrobial Agents and Chemotherapy.

[3]  Jerome J. Schentag,et al.  Achieving an Optimal Outcome in the Treatment of Infections , 1999, Clinical pharmacokinetics.

[4]  T. Mazzei,et al.  Clarithromycin: pharmacokinetic and pharmacodynamic interrelationships and dosage regimen. , 1999, Journal of chemotherapy.

[5]  W. Craig,et al.  In Vivo Activities of Amoxicillin and Amoxicillin-Clavulanate against Streptococcus pneumoniae: Application to Breakpoint Determinations , 1998, Antimicrobial Agents and Chemotherapy.

[6]  H. Verbrugh,et al.  Comparison of Pharmacodynamics of Azithromycin and Erythromycin In Vitro and In Vivo , 1998, Antimicrobial Agents and Chemotherapy.

[7]  C. Nightingale.  Pharmacokinetics and pharmacodynamics of newer macrolides. , 1997, The Pediatric infectious disease journal.

[8]  S. Mitsuhashi,et al.  In vitro and in vivo antibacterial activities of clarithromycin. , 1996, Chemotherapy.

[9]  W. Craig,et al.  Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. , 1996, The Pediatric infectious disease journal.

[10]  L. Tissi,et al.  In vivo efficacy of azithromycin in treatment of systemic infection and septic arthritis induced by type IV group B Streptococcus strains in mice: comparative study with erythromycin and penicillin G , 1995, Antimicrobial agents and chemotherapy.

[11]  W. Craig.  Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. , 1995, Diagnostic microbiology and infectious disease.

[12]  M. Kaku,et al.  In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae , 1994, Antimicrobial Agents and Chemotherapy.

[13]  J. Pocidalo,et al.  Correlation between macrolide lung pharmacokinetics and therapeutic efficacy in a mouse model of pneumococcal pneumonia. , 1993, The Journal of antimicrobial chemotherapy.

[14]  J. Cavanaugh,et al.  Single‐ and Multiple‐dose Pharmacokinetics of Clarithromycin, a New Macrolide Antimicrobial , 1993, Journal of clinical pharmacology.

[15]  J. Spivey.  The postantibiotic effect. , 1992, Clinical pharmacy.

[16]  M. Muffat‐Joly,et al.  Prophylactic and therapeutic activities of azithromycin in a mouse model of pneumococcal pneumonia , 1991, Antimicrobial Agents and Chemotherapy.

[17]  W. Craig,et al.  Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. , 1989, The Journal of infectious diseases.

[18]  R. Sutherland,et al.  Comparative Effects of Amoxycillin and Ampicillin in the Treatment of Experimental Mouse Infections , 1975, Antimicrobial Agents and Chemotherapy.

[19]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[20]  W. Craig,et al.  Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  A. Girard,et al.  The comparative activity of azithromycin, macrolides and amoxycillin against streptococci in experimental infections. , 1993, The Journal of antimicrobial chemotherapy.

[22]  W. Craig.  Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man. , 1993, The Journal of antimicrobial chemotherapy.